|
시장보고서
상품코드
1873695
세계의 악성 중피종 치료제 시장 : 시장 점유율과 순위, 전체 판매 및 수요 예측(2025-2031년)Malignant Mesothelioma Therapeutic - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 |
||||||
QYResearch
세계의 악성 중피종 치료제 시장 규모는 2024년에 3억 7,700만 달러로 추정되며, 2025년부터 2031년까지 예측 기간 동안 CAGR 7.0%로 성장하여 2031년까지 6억 200만 달러로 확대될 것으로 예측됩니다.
중피종은 많은 내부 장기를 덮고 있는 얇은 조직층(중피)에서 발생하는 암의 일종입니다. 악성 중피종은 폐, 흉벽, 복부를 덮고 있는 얇은 조직(중피)에 발생하는 암입니다. 중피종의 주요 위험 요인은 석면 노출입니다.
악성 중피종 치료제 시장은 주로 개발도상국의 석면 노출 사례 증가와 직업 근로자의 질병 인식 증가로 인해 주도되고 있습니다. 특히 면역관문억제제와 VEGF 억제제를 중심으로 한 면역치료 및 표적 치료제의 괄목할 만한 발전은 치료 성과에 혁명을 가져오고 있습니다. FDA의 희귀질환 치료제 신속 승인 제도와 희귀암 치료제에 대한 연구개발 투자 증가는 시장의 성장을 더욱 촉진하고 있습니다. 또한, 조기 발견을 가능하게 하는 진단 기술의 향상과 바이오마커를 기반으로 한 맞춤형 의료 접근법이 급증하면서 새로운 치료 기회를 창출하고 있습니다.
이 시장은 환자 대부분이 진행성 질환으로 진단되어 치료 효과에 상당한 제약이 있는 등 심각한 장벽에 직면해 있습니다. 높은 치료제의 개발 비용과 중피종의 희귀성으로 인한 환자 수의 제한은 제약사들에게 상업적 타당성에 대한 우려를 불러일으키고 있습니다. 선진국의 엄격한 석면 규제는 발병률을 낮추고 있으며, 역설적으로 대상 시장을 축소시키고 있습니다. 또한, 표준화된 치료 프로토콜의 부재와 빈번한 화학요법 내성은 임상적 관리의 중요한 도전이 되고 있습니다. 한편, 많은 의료 시스템에서 고가의 새로운 치료법에 대한 상환 문제가 환자의 접근을 제한하고 있습니다.
이 보고서는 악성 중피종 치료제 세계 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위를 중심으로 지역 및 국가, 유형 및 적응증별 분석을 종합적으로 제시하는 것을 목적으로 합니다.
악성 중피종 치료제 시장 규모, 추정치 및 예측치는 매출액 기준으로 제시되며, 2024년을 기준 연도로 하여 2020년부터 2031년까지의 기간의 과거 데이터와 예측 데이터를 포함합니다. 정량적 분석과 정성적 분석을 통해 독자들이 사업/성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 포지셔닝 분석, 악성 중피종 치료제 관련 정보에 입각한 사업적 판단을 내릴 수 있도록 돕습니다.
시장 세분화
기업별
- Eli Lilly
- Teva
- Sanofi
- Bristol-Myers Squibb
- Pfizer
- Roche
- Merck
- Ono Pharmaceutical
- Mylan
- Fresenius Kabi
- Sun Pharmaceuticals
- Eagle Pharmaceuticals
- Qilu Pharma
- Sichuan Huiyu Pharma
- Nippon Kayaku
- Jiangsu Haosen
- Amgen
유형별 부문
- 페메트렉시드
- 시스플라틴
- 면역요법제
- 기타
용도별 부문
- 흉막 중피종
- 복막 중피종
- 기타
지역별
- 북미
- 미국
- 캐나다
- 아시아태평양
- 중국
- 일본
- 한국
- 동남아시아
- 인도
- 호주
- 기타 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 네덜란드
- 북유럽 국가
- 기타 유럽
- 라틴아메리카
- 멕시코
- 브라질
- 기타 라틴아메리카
- 중동 및 아프리카
- 튀르키예
- 사우디아라비아
- 아랍에미리트
- 기타 중동 및 아프리카
자주 묻는 질문
The global market for Malignant Mesothelioma Therapeutic was estimated to be worth US$ 377 million in 2024 and is forecast to a readjusted size of US$ 602 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium). Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.
The malignant mesothelioma therapeutics market is primarily driven by increasing asbestos exposure cases in developing nations and rising disease awareness among occupational workers. Significant advancements in immunotherapy and targeted therapies, particularly immune checkpoint inhibitors and VEGF inhibitors, are revolutionizing treatment outcomes. The FDA's accelerated approval pathway for orphan drugs and growing R&D investments in rare cancer treatments are further propelling market growth. Additionally, improved diagnostic techniques enabling earlier detection and a surge in biomarker-driven personalized medicine approaches are creating new therapeutic opportunities.
The market faces substantial hurdles including late-stage diagnosis in most patients, severely limiting treatment efficacy. High development costs for novel therapies and limited patient pools due to mesothelioma's rarity create commercial viability concerns for pharmaceutical companies. Stringent asbestos regulations in developed countries are reducing incident rates, paradoxically shrinking the addressable market. Furthermore, the lack of standardized treatment protocols and frequent chemotherapy resistance present significant clinical management challenges, while reimbursement issues for expensive emerging therapies restrict patient access in many healthcare systems.
This report aims to provide a comprehensive presentation of the global market for Malignant Mesothelioma Therapeutic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Malignant Mesothelioma Therapeutic by region & country, by Type, and by Application.
The Malignant Mesothelioma Therapeutic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Malignant Mesothelioma Therapeutic.
Market Segmentation
By Company
- Eli Lilly
- Teva
- Sanofi
- Bristol-Myers Squibb
- Pfizer
- Roche
- Merck
- Ono Pharmaceutical
- Mylan
- Fresenius Kabi
- Sun Pharmaceuticals
- Eagle Pharmaceuticals
- Qilu Pharma
- Sichuan Huiyu Pharma
- Nippon Kayaku
- Jiangsu Haosen
- Amgen
Segment by Type
- Pemetrexed
- Cisplatin
- Immunotherapy Agents
- Others
Segment by Application
- Pleural Mesothelioma
- Peritoneal Mesothelioma
- Others
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Malignant Mesothelioma Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Malignant Mesothelioma Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Malignant Mesothelioma Therapeutic in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Malignant Mesothelioma Therapeutic Product Introduction
- 1.2 Global Malignant Mesothelioma Therapeutic Market Size Forecast (2020-2031)
- 1.3 Malignant Mesothelioma Therapeutic Market Trends & Drivers
- 1.3.1 Malignant Mesothelioma Therapeutic Industry Trends
- 1.3.2 Malignant Mesothelioma Therapeutic Market Drivers & Opportunity
- 1.3.3 Malignant Mesothelioma Therapeutic Market Challenges
- 1.3.4 Malignant Mesothelioma Therapeutic Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Malignant Mesothelioma Therapeutic Players Revenue Ranking (2024)
- 2.2 Global Malignant Mesothelioma Therapeutic Revenue by Company (2020-2025)
- 2.3 Key Companies Malignant Mesothelioma Therapeutic Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Malignant Mesothelioma Therapeutic Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Malignant Mesothelioma Therapeutic
- 2.6 Malignant Mesothelioma Therapeutic Market Competitive Analysis
- 2.6.1 Malignant Mesothelioma Therapeutic Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Malignant Mesothelioma Therapeutic Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Malignant Mesothelioma Therapeutic as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 Pemetrexed
- 3.1.2 Cisplatin
- 3.1.3 Immunotherapy Agents
- 3.1.4 Others
- 3.2 Global Malignant Mesothelioma Therapeutic Sales Value by Type
- 3.2.1 Global Malignant Mesothelioma Therapeutic Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Malignant Mesothelioma Therapeutic Sales Value, by Type (2020-2031)
- 3.2.3 Global Malignant Mesothelioma Therapeutic Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Pleural Mesothelioma
- 4.1.2 Peritoneal Mesothelioma
- 4.1.3 Others
- 4.2 Global Malignant Mesothelioma Therapeutic Sales Value by Application
- 4.2.1 Global Malignant Mesothelioma Therapeutic Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Malignant Mesothelioma Therapeutic Sales Value, by Application (2020-2031)
- 4.2.3 Global Malignant Mesothelioma Therapeutic Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Malignant Mesothelioma Therapeutic Sales Value by Region
- 5.1.1 Global Malignant Mesothelioma Therapeutic Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Malignant Mesothelioma Therapeutic Sales Value by Region (2020-2025)
- 5.1.3 Global Malignant Mesothelioma Therapeutic Sales Value by Region (2026-2031)
- 5.1.4 Global Malignant Mesothelioma Therapeutic Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 5.2.2 North America Malignant Mesothelioma Therapeutic Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 5.3.2 Europe Malignant Mesothelioma Therapeutic Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 5.4.2 Asia Pacific Malignant Mesothelioma Therapeutic Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 5.5.2 South America Malignant Mesothelioma Therapeutic Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Malignant Mesothelioma Therapeutic Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Malignant Mesothelioma Therapeutic Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 6.3.2 United States Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Malignant Mesothelioma Therapeutic Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 6.4.2 Europe Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Malignant Mesothelioma Therapeutic Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 6.5.2 China Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Malignant Mesothelioma Therapeutic Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 6.6.2 Japan Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Malignant Mesothelioma Therapeutic Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 6.7.2 South Korea Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Malignant Mesothelioma Therapeutic Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 6.8.2 Southeast Asia Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Malignant Mesothelioma Therapeutic Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 6.9.2 India Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Malignant Mesothelioma Therapeutic Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 Eli Lilly
- 7.1.1 Eli Lilly Profile
- 7.1.2 Eli Lilly Main Business
- 7.1.3 Eli Lilly Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.1.4 Eli Lilly Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.1.5 Eli Lilly Recent Developments
- 7.2 Teva
- 7.2.1 Teva Profile
- 7.2.2 Teva Main Business
- 7.2.3 Teva Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.2.4 Teva Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.2.5 Teva Recent Developments
- 7.3 Sanofi
- 7.3.1 Sanofi Profile
- 7.3.2 Sanofi Main Business
- 7.3.3 Sanofi Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.3.4 Sanofi Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.3.5 Sanofi Recent Developments
- 7.4 Bristol-Myers Squibb
- 7.4.1 Bristol-Myers Squibb Profile
- 7.4.2 Bristol-Myers Squibb Main Business
- 7.4.3 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.4.4 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.4.5 Bristol-Myers Squibb Recent Developments
- 7.5 Pfizer
- 7.5.1 Pfizer Profile
- 7.5.2 Pfizer Main Business
- 7.5.3 Pfizer Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.5.4 Pfizer Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.5.5 Pfizer Recent Developments
- 7.6 Roche
- 7.6.1 Roche Profile
- 7.6.2 Roche Main Business
- 7.6.3 Roche Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.6.4 Roche Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.6.5 Roche Recent Developments
- 7.7 Merck
- 7.7.1 Merck Profile
- 7.7.2 Merck Main Business
- 7.7.3 Merck Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.7.4 Merck Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.7.5 Merck Recent Developments
- 7.8 Ono Pharmaceutical
- 7.8.1 Ono Pharmaceutical Profile
- 7.8.2 Ono Pharmaceutical Main Business
- 7.8.3 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.8.4 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.8.5 Ono Pharmaceutical Recent Developments
- 7.9 Mylan
- 7.9.1 Mylan Profile
- 7.9.2 Mylan Main Business
- 7.9.3 Mylan Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.9.4 Mylan Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.9.5 Mylan Recent Developments
- 7.10 Fresenius Kabi
- 7.10.1 Fresenius Kabi Profile
- 7.10.2 Fresenius Kabi Main Business
- 7.10.3 Fresenius Kabi Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.10.4 Fresenius Kabi Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.10.5 Fresenius Kabi Recent Developments
- 7.11 Sun Pharmaceuticals
- 7.11.1 Sun Pharmaceuticals Profile
- 7.11.2 Sun Pharmaceuticals Main Business
- 7.11.3 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.11.4 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.11.5 Sun Pharmaceuticals Recent Developments
- 7.12 Eagle Pharmaceuticals
- 7.12.1 Eagle Pharmaceuticals Profile
- 7.12.2 Eagle Pharmaceuticals Main Business
- 7.12.3 Eagle Pharmaceuticals Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.12.4 Eagle Pharmaceuticals Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.12.5 Eagle Pharmaceuticals Recent Developments
- 7.13 Qilu Pharma
- 7.13.1 Qilu Pharma Profile
- 7.13.2 Qilu Pharma Main Business
- 7.13.3 Qilu Pharma Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.13.4 Qilu Pharma Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.13.5 Qilu Pharma Recent Developments
- 7.14 Sichuan Huiyu Pharma
- 7.14.1 Sichuan Huiyu Pharma Profile
- 7.14.2 Sichuan Huiyu Pharma Main Business
- 7.14.3 Sichuan Huiyu Pharma Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.14.4 Sichuan Huiyu Pharma Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.14.5 Sichuan Huiyu Pharma Recent Developments
- 7.15 Nippon Kayaku
- 7.15.1 Nippon Kayaku Profile
- 7.15.2 Nippon Kayaku Main Business
- 7.15.3 Nippon Kayaku Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.15.4 Nippon Kayaku Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.15.5 Nippon Kayaku Recent Developments
- 7.16 Jiangsu Haosen
- 7.16.1 Jiangsu Haosen Profile
- 7.16.2 Jiangsu Haosen Main Business
- 7.16.3 Jiangsu Haosen Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.16.4 Jiangsu Haosen Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.16.5 Jiangsu Haosen Recent Developments
- 7.17 Amgen
- 7.17.1 Amgen Profile
- 7.17.2 Amgen Main Business
- 7.17.3 Amgen Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.17.4 Amgen Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.17.5 Amgen Recent Developments
8 Industry Chain Analysis
- 8.1 Malignant Mesothelioma Therapeutic Industrial Chain
- 8.2 Malignant Mesothelioma Therapeutic Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Malignant Mesothelioma Therapeutic Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Malignant Mesothelioma Therapeutic Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
